Superior T

Superior T is a Munich-based biotechnology company specializing in the development of next-generation adoptive T-cell therapies for cancer and infectious diseases. A spin-off from the Technical University of Munich (TUM), the company leverages a proprietary platform to identify and validate high-performance T-cell receptors (TCRs) with optimal affinity and sensitivity. Their technology focuses on selecting TCRs that can trigger potent immune responses even at low antigen densities, addressing a key limitation of current immunotherapies. Superior T aims to provide engineered T-cell products with enhanced safety and durability, particularly for the treatment of solid tumors. The company is currently advancing its lead candidates through pre-clinical development toward first-in-human clinical trials.